|
|
||||||||
Departments of Nuclear Medicine and Medicine (Division of Cardiology), University of Massachusetts Medical Center, Worcester, Massachusetts
Department of Physiology, University of the Pacific, Stockton, California
Correspondence: For correspondence or reprints contact: Seth T. Dahlberg, MD, Department of Nuclear Medicine, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655.
ABSTRACT
Technetium-99m-[2-(1-methoxybutyl) isonitrile] (MBI) is a potential new compound for the scintigraphic imaging of coronary flow. Evaluation in the blood-perfused isolated rabbit heart model showed this compound to have a myocardial uptake comparable to 201Tl and higher than sestamibi. Although the mean ± s.d. maximum extraction (Emax and capillary permeability-surface area product (PScap) of 99mTc-MBI (Emax = 0.45 ± 0.10, PScap = 1.07 ± 0.47 ml/min · g) were much less than 201 (Emax = 0.71 ± 0.07, PScap = 2.21 ± 0.76 ml/min · g, p < 0.0001), the net extraction of 99mTc-MBI (Enet = 0.52 ± 0.10) was only slightly less than the value for 201Tl (Enet = 0.56 ± 0.10, p < 0.05). There was no significant difference in the myocardial uptake versus flow between 99mTc-MBI and 201Tl. These data indicate that assessment of relative coronary flow based on the myocardial uptake of 99mTc-MBI should give results comparable to 201Tl. Therefore, 99mTc-MBI may have clinical potential as a radiolabeled myocardial perfusion agent.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |